ヒト免疫不全ウイルス(HIV)感染症(AIDS)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0880
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月1日
◆ページ数:1202
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥525,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2020, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 1, 14, 48, 47, 1, 6, 102, 64 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 3, 15, 28, 49 and 66 molecules, respectively.

Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Human Immunodeficiency Virus (HIV) Infections (AIDS) – Overview
Human Immunodeficiency Virus (HIV) Infections (AIDS) – Therapeutics Development
Human Immunodeficiency Virus (HIV) Infections (AIDS) – Therapeutics Assessment
Human Immunodeficiency Virus (HIV) Infections (AIDS) – Companies Involved in Therapeutics Development
Human Immunodeficiency Virus (HIV) Infections (AIDS) – Drug Profiles
Human Immunodeficiency Virus (HIV) Infections (AIDS) – Dormant Projects
Human Immunodeficiency Virus (HIV) Infections (AIDS) – Discontinued Products
Human Immunodeficiency Virus (HIV) Infections (AIDS) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by 2A Pharma AB, H1 2020
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AbbVie Inc, H1 2020
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Abivax SA, H1 2020
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Actinobac Biomed Inc, H1 2020
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AdAlta Ltd, H1 2020
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects, H1 2020
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products, H1 2020

【掲載企業】

2A Pharma AB
AbbVie Inc
Abivax SA
Actinobac Biomed Inc
AdAlta Ltd
Advanced Genetic Systems Inc
Aelix Therapeutics SL
AIM ImmunoTech Inc
Akshaya Bio Inc
AlbaJuna Therapeutics
Altor Bioscience LLC
American Gene Technologies International Inc
Aphios Corp
Apimeds Inc
Atreca Inc
AUM LifeTech Inc
Auritec Pharmaceuticals Inc
Avixgen Inc
B Cell Design SAS
Biological Mimetics Inc
Bionor Holding AS
BioNTech SE
Biosantech SA
Biotron Ltd
Bolder Biotechnology Inc
Brandenburg Antiinfektiva GmbH
Bristol-Myers Squibb Co
BryoLogyx Inc
Bukwang Pharm Co Ltd
Cadila Healthcare Ltd
Califia Bio Inc
Celdara Medical LLC
Celldex Therapeutics Inc
Chiesi Farmaceutici SpA
Chipscreen Biosciences Ltd
Cidara Therapeutics Inc
Clover Biopharmaceuticals
Cocrystal Pharma Inc
Collaborations Pharmaceuticals Inc
Consegna Pharma Inc
CSL Ltd
Curevac AG
Cytocom Inc
Cytodyn Inc
CytRx Corp
DFH Pharma Inc
Diaccurate
E-Vaccines Inc
Emergent BioSolutions Inc
Emmune Inc
Enochian Biosciences Inc
Enzo Biochem Inc
EpiVax Inc
eTheRNA Immunotherapies NV
Evotec SE
Excision BioTherapeutics Inc
ExQor Technologies Inc
FIT Biotech Oy (Inactive)
Fox Chase Chemical Diversity Center Inc
Frontier Biotechnologies Inc
Fujifilm Toyama Chemical Co Ltd
GB Sciences Inc
GeneCure LLC
Genetic Immunity Inc
GeoVax Labs Inc
Gilead Sciences Inc
Globeimmune Inc
Greffex Inc
GT Biopharma Inc
Helocyte Biosciences Inc
Henan Zhenshi Biotechnology Co Ltd
Hepion Pharmaceuticals Inc
Hetero Drugs Ltd
Hoverink Biotechnologies Inc
iCo Therapeutics Inc
ID Pharma Co Ltd
IGXBio Inc
Immune Modulation Inc
Immune Response BioPharma Inc
Immunologik GmbH
Immunotope Inc
ImQuest Life Sciences Inc
Innovare R & D SA De CV
Inovio Pharmaceuticals Inc
Intarcia Therapeutics Inc
Intrucept Biomedicine LLC
InvVax Inc
ISR Immune System Regulation Holding AB
Jericho Sciences LLC
Jiangsu Aidea Pharmaceutical Co Ltd
Johnson & Johnson
Kainos Medicine Inc
Kanglin Biotech Hangzhou Co Ltd
Karyopharm Therapeutics Inc
Kymab Ltd
Laboratory Biodim
Lauren Sciences LLC
Longevity Biotech Inc
Looove Biotechnology Beijing Co Ltd
Lyndra Inc
MacroGenics Inc
Mapp Biopharmaceutical Inc
Merck & Co Inc
Miltenyi Biotec GmbH
Minka Therapeutics SA
Molecular Express Inc
Mologen AG
Mutabilis SA
Mycenax Biotech Inc
Mymetics Corp
NanoViricides Inc
Navigen Inc
NeED Pharma srl
New World Laboratories Inc
NovalGen Ltd
Novodux
Omeros Corp
Oncologie Inc
Oncolys BioPharma Inc
Oncotelic Inc
Oncovir Inc
Orbis Biosciences Inc
Orion Biotechnology Canada Ltd
Osel Inc
OyaGen Inc
Palisades Therapeutics
Pepscan Therapeutics BV
Phoenix Biotechnology Inc
PlantForm Corp
Polyrizon Ltd
Profectus BioSciences Inc
Protheragen Inc
ReceptoPharm Inc
Recombio SL
Repair Biotechnologies Inc
Resverlogix Corp
RetroVirox Inc
Rodos BioTarget GmbH
Samjin Pharm Co Ltd
Sangamo Therapeutics Inc
Savoy Pharmaceuticals Inc
Secura Bio Inc
Serum Institute of India Ltd
Shanghai Pharmaceutical Group Co Ltd
Shionogi & Co Ltd
SignalRx Pharmaceuticals Inc
Sirga Advanced Biopharma Inc
SMET Pharmaceutical Inc
ST Pharm Co Ltd
Staidson BioPharma Inc
Starpharma Holdings Ltd
Sumagen Co Ltd
Sunomix Therapeutics
Susavion Biosciences Inc
Taiga Biotechnologies Inc
TaiMed Biologics Inc
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
Targeted Pharmaceuticals LLC
TechnoVax Inc
TeneoBio Inc
Tetranov International Inc
TGV Laboratories Inc
TheraJect Inc
Theratechnologies Inc
Theravectys SA
Transgene Biotek Ltd
TVAX Biomedical Inc
United Biomedical Inc
Vaccibody AS
Vault Pharma Inc
VG Life Sciences Inc
Vichem Chemie Research Ltd
ViiV Healthcare UK Ltd
Vincogen Corp
Vir Biotechnology Inc
Viramatix Sdn Bhd
Viravaxx AG
Viriom Inc
ViroStatics SRL
ViroXis SAS
Winsantor Inc
XL-protein GmbH
Xyphos Biosciences Inc
Yaso Therapeutics Inc
Yisheng Biopharma Co Ltd
Zata Pharmaceuticals Inc
Zion Medical

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ヒト免疫不全ウイルス(HIV)感染症(AIDS)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆